Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial

BACKGROUND: To investigate the long-term efficacy and safety of empagliflozin monotherapy compared with placebo and sitagliptin in drug-naïve patients with type 2 diabetes mellitus. METHODS: Of 899 patients randomized to receive empagliflozin 10 mg, empagliflozin 25 mg, placebo, or sitagliptin 100 m...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cardiovasc Diabetol
Glavni autori: Roden, Michael, Merker, Ludwig, Christiansen, Anita Vedel, Roux, Flavien, Salsali, Afshin, Kim, Gabriel, Stella, Peter, Woerle, Hans J., Broedl, Uli C.
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2015
Teme:
Original Investigation
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4690334/
https://ncbi.nlm.nih.gov/pubmed/26701110
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-015-0314-0
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items